Fact Sheet – NASH Clinical Trials at Cerba Research

Aramchol, Scd1 Inhibitor, Improves Liver Glucose Homeostasis In NASH

Metabolomic Characterization Of Very Early Hepatocellular Carcinoma In Cirrhotic Patients Submitted For Liver Transplantation

Non-Invasive Serum Lipidomic Approach To Discriminate Non-Alcoholic Steatohepatitis In Multiethnic Patients With Type 2 Diabetes Mellitus

Obese Patients Carrying NAFLD-Associated Genetic Variants Present Specific Serum and Liver Lipidomic Profiles: Identification of a Lipidomic Signature in Serum to Estimate the Liver Fat Content